In this study, we first retrospectively analyzed the relationship between the peak daily dose (PDD) to achieve good glycemic control and clinical parameters in 104 hospitalized patients with T2D who started insulin therapy with BBT. The gene discussed is INS; the disease is type 2 diabetes mellitus.